SA516371613B1 - Cgrp صيغة قرص لمركبات نشطة تجاه - Google Patents
Cgrp صيغة قرص لمركبات نشطة تجاهInfo
- Publication number
- SA516371613B1 SA516371613B1 SA516371613A SA516371613A SA516371613B1 SA 516371613 B1 SA516371613 B1 SA 516371613B1 SA 516371613 A SA516371613 A SA 516371613A SA 516371613 A SA516371613 A SA 516371613A SA 516371613 B1 SA516371613 B1 SA 516371613B1
- Authority
- SA
- Saudi Arabia
- Prior art keywords
- cgrp
- active compounds
- tablet formulation
- api
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
يتم توجيه هذا الاختراع لتركيبات تتألف من مادة ناتج بثق extrudate أو محلول صلب من مركب، أو ملح منه، له الصيغة 1 ( مكون صيدلاني فعال active pharmaceutical ingredients " API " ) : الصيغة 1، حيث "Ra" هى بشكل مستقل -H أو - F، في قالب البوليمر polymer matrix القابل للذوبان في الماء والذي يتضمن كذلك نظام تفتيت يسمح للقرص المصنوع منه بالتفتت disintegration بسرعة في البيئة التي سيتم إطلاق مكون صيدلاني فعال active pharmaceutical ingredients ( API ) فيها. شكل 3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461936019P | 2014-02-05 | 2014-02-05 | |
US201462087366P | 2014-12-04 | 2014-12-04 | |
PCT/US2015/013672 WO2015119848A1 (en) | 2014-02-05 | 2015-01-30 | Tablet formulation for cgrp-active compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SA516371613B1 true SA516371613B1 (ar) | 2021-06-19 |
Family
ID=53778348
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SA516371613A SA516371613B1 (ar) | 2014-02-05 | 2016-08-04 | Cgrp صيغة قرص لمركبات نشطة تجاه |
Country Status (13)
Country | Link |
---|---|
US (4) | US10117836B2 (ar) |
EP (1) | EP3102564A4 (ar) |
JP (2) | JP6491669B2 (ar) |
KR (3) | KR102448369B1 (ar) |
CN (2) | CN112022818A (ar) |
AU (4) | AU2015214502B2 (ar) |
CA (1) | CA2937315A1 (ar) |
HK (1) | HK1232218A1 (ar) |
IL (1) | IL246828B (ar) |
MX (2) | MX2016010169A (ar) |
RU (2) | RU2696578C1 (ar) |
SA (1) | SA516371613B1 (ar) |
WO (1) | WO2015119848A1 (ar) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI522355B (zh) * | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑 |
KR102448369B1 (ko) | 2014-02-05 | 2022-09-28 | 머크 샤프 앤드 돔 엘엘씨 | Cgrp-활성 화합물에 대한 정제 제제 |
CN105126111A (zh) * | 2015-09-30 | 2015-12-09 | 清华大学 | 提高索拉非尼生物利用度的制剂 |
IL269668B2 (en) * | 2017-03-30 | 2023-09-01 | Merck Patent Gmbh | Pharmaceutical preparations containing (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol and their preparation |
MX2020009856A (es) * | 2018-03-25 | 2020-10-08 | Biohaven Pharm Holding Co Ltd | Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp). |
RU2755571C1 (ru) * | 2020-06-09 | 2021-09-17 | Сергей Геннадьевич Каплунов | Способ изготовления гравюры на металле |
EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals Int Ltd | TREATMENT OF MIGRAINE |
AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
DE3612212A1 (de) | 1986-04-11 | 1987-10-15 | Basf Ag | Verfahren zur herstellung von festen pharmazeutischen formen |
TW486370B (en) | 1996-12-25 | 2002-05-11 | Yamanouchi Pharma Co Ltd | Rapidly disintegrable pharmaceutical composition |
US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
US20040076668A1 (en) * | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
CA2519515A1 (en) | 2003-03-14 | 2004-10-14 | Merck & Co., Inc. | Benodiazepine spirohydantoin cgrp receptor antagonists |
JP4690313B2 (ja) | 2003-03-14 | 2011-06-01 | メルク・シャープ・エンド・ドーム・コーポレイション | カルボキサミドスピロヒダントインcgrp受容体アンタゴニスト |
JO2355B1 (ar) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | مضادات مستقبل ببتيد كالسيتونين الوراثي |
US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
CA2579847A1 (en) | 2004-09-13 | 2006-03-23 | Merck & Co., Inc. | Bicyclic anilide spirolactam cgrp receptor antagonists |
DE102004063755A1 (de) * | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
CN101208303A (zh) | 2005-03-14 | 2008-06-25 | 默克公司 | Cgrp受体拮抗剂 |
CN101378731B (zh) | 2006-02-09 | 2014-03-05 | 默沙东公司 | Cetp抑制剂的聚合物制剂 |
EP2029575B1 (en) | 2006-05-09 | 2014-10-22 | Merck Sharp & Dohme Corp. | Substituted spirocyclic cgrp receptor antagonists |
US8993588B2 (en) | 2007-06-05 | 2015-03-31 | Merck Sharp & Dohme Corp. | Carboxamide heterocyclic CGRP receptor antagonists |
EP2205599B1 (de) | 2007-10-18 | 2012-06-06 | Boehringer Ingelheim International GmbH | Cgrp-antagonisten |
CA2705599A1 (en) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | New compounds |
EP2249833B1 (en) | 2008-02-05 | 2012-10-17 | Merck Sharp & Dohme Corp. | Prodrugs of cgrp receptor antagonist |
US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
CL2009000902A1 (es) | 2008-04-15 | 2010-07-23 | Merck Sharp & Dohme | Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica. |
EP3222277B1 (en) * | 2009-03-31 | 2020-02-26 | Ligand Pharmaceuticals Inc. | A biphenylsulfonamide endothelin and angiotensin ii receptor antagonist to treat glomerulosclerosis and iga-induced nephropathy |
WO2010139717A1 (de) | 2009-06-05 | 2010-12-09 | Boehringer Ingelheim International Gmbh | Neue verbindungen |
NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
UA113500C2 (xx) * | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
TWI522355B (zh) | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑 |
JP2013542261A (ja) | 2010-11-12 | 2013-11-21 | メルク・シャープ・アンド・ドーム・コーポレーション | ピペリジノンカルボキサミドインダンcgrp受容体アンタゴニスト |
US8895572B2 (en) | 2010-12-22 | 2014-11-25 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide CGRP receptor antagonists |
EP2654423B1 (en) | 2010-12-22 | 2016-12-07 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide cgrp receptor antagonists |
JP2014507424A (ja) * | 2011-03-08 | 2014-03-27 | ザリカス ファーマスーティカルズ リミテッド | 固体分散物製剤およびその使用方法 |
EP2685826B1 (en) | 2011-03-18 | 2016-02-03 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
EP2753640B1 (en) | 2011-09-08 | 2016-03-09 | Codexis, Inc. | Biocatalysts and methods for the synthesis of substituted lactams |
BR122020010643B1 (pt) | 2011-10-14 | 2022-05-17 | Array Biopharma Inc | Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida |
AU2013232191B2 (en) | 2012-03-14 | 2017-03-30 | Merck Sharp & Dohme Llc | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
US9487523B2 (en) | 2012-03-14 | 2016-11-08 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
BR112014026880A2 (pt) | 2012-04-25 | 2017-06-27 | Centric Res Institute | composição de sensibilização e método de uso |
US9227972B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam CGRP receptor antagonists |
EP2846801B1 (en) | 2012-05-09 | 2017-04-05 | Merck Sharp & Dohme Corp. | Pyridine cgrp receptor antagonists |
US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
US9296750B2 (en) | 2012-05-09 | 2016-03-29 | Merck Sharp & Dohme Corp. | Spirolactam CGRP receptor antagonists |
ES2769879T3 (es) | 2013-03-15 | 2020-06-29 | Tonix Pharma Holdings Ltd | Formulaciones eutécticas de clorhidrato de ciclobenzaprina y manitol |
KR20220108207A (ko) | 2013-09-16 | 2022-08-02 | 머크 샤프 앤드 돔 코포레이션 | Cgrp 수용체 길항제를 위한 제제 |
KR102448369B1 (ko) | 2014-02-05 | 2022-09-28 | 머크 샤프 앤드 돔 엘엘씨 | Cgrp-활성 화합물에 대한 정제 제제 |
US20160346198A1 (en) | 2014-02-05 | 2016-12-01 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
KR20170003527A (ko) | 2014-02-24 | 2017-01-09 | 유리젠 파마슈티컬스, 인코포레이티드 | 경구 투여용 펜토산 폴리설페이트 염의 조성물 |
BR112017000865A2 (pt) | 2014-08-22 | 2017-12-05 | Clovis Oncology Inc | comprimidos de rucaparibe de concentração de dosagem alta |
TW201642853A (zh) | 2015-01-23 | 2016-12-16 | 歌林達有限公司 | 用於治療肝功能之損傷及/或腎功能之損傷個體疼痛之西博帕多(Cebranopadol) |
MX2018003713A (es) | 2015-09-24 | 2018-08-15 | Teva Pharmaceuticals Int Gmbh | Prevencion, tratamiento y reduccion del dolor de cabeza postraumatico (persistente). |
US20180092899A1 (en) | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
WO2018160897A1 (en) | 2017-03-02 | 2018-09-07 | Beth Israel Deaconess Medical Center, Inc. | Preventing post-ictal headaches |
TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
US20190135927A1 (en) | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
US20190374518A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
US20190374520A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
TWI826514B (zh) | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
AU2020259461A1 (en) | 2019-04-18 | 2021-11-11 | Allergan Sales, Llc | CGRP antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
US20220340650A1 (en) | 2019-09-25 | 2022-10-27 | Abnijeet JAKATE | Combination therapy with cgrp antagonists |
EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals Int Ltd | TREATMENT OF MIGRAINE |
AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
US20230130736A1 (en) | 2021-09-27 | 2023-04-27 | Allergan Pharmaceuticals International Limited | Methods of treating migraine |
-
2015
- 2015-01-30 KR KR1020167024025A patent/KR102448369B1/ko active IP Right Grant
- 2015-01-30 KR KR1020227032939A patent/KR20220136460A/ko not_active Application Discontinuation
- 2015-01-30 CN CN202010812438.5A patent/CN112022818A/zh active Pending
- 2015-01-30 WO PCT/US2015/013672 patent/WO2015119848A1/en active Application Filing
- 2015-01-30 EP EP15746768.9A patent/EP3102564A4/en active Pending
- 2015-01-30 RU RU2016135536A patent/RU2696578C1/ru active
- 2015-01-30 MX MX2016010169A patent/MX2016010169A/es unknown
- 2015-01-30 US US15/115,026 patent/US10117836B2/en active Active
- 2015-01-30 CA CA2937315A patent/CA2937315A1/en active Pending
- 2015-01-30 JP JP2016548023A patent/JP6491669B2/ja active Active
- 2015-01-30 RU RU2019123406A patent/RU2019123406A/ru unknown
- 2015-01-30 AU AU2015214502A patent/AU2015214502B2/en active Active
- 2015-01-30 CN CN201580006288.6A patent/CN105960397B/zh active Active
- 2015-01-30 KR KR1020237022803A patent/KR20230107902A/ko active Search and Examination
-
2016
- 2016-07-18 IL IL246828A patent/IL246828B/en active IP Right Grant
- 2016-08-04 SA SA516371613A patent/SA516371613B1/ar unknown
- 2016-08-04 MX MX2021006790A patent/MX2021006790A/es unknown
-
2017
- 2017-06-13 HK HK17105813.5A patent/HK1232218A1/zh unknown
-
2018
- 2018-11-02 US US16/178,641 patent/US20190209478A1/en not_active Abandoned
-
2019
- 2019-03-04 JP JP2019038349A patent/JP6666490B2/ja active Active
- 2019-09-06 AU AU2019226239A patent/AU2019226239B2/en active Active
-
2020
- 2020-12-03 US US17/110,398 patent/US11925709B2/en active Active
-
2021
- 2021-10-08 AU AU2021245229A patent/AU2021245229A1/en not_active Abandoned
-
2023
- 2023-04-21 US US18/137,925 patent/US20230248655A1/en active Pending
- 2023-10-30 AU AU2023258317A patent/AU2023258317A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SA516371613B1 (ar) | Cgrp صيغة قرص لمركبات نشطة تجاه | |
PH12018502747A1 (en) | Boronic acid derivatives and therapeutic uses thereof | |
PH12017501413A1 (en) | Substituted nucleoside derivatives useful as anticancer agents | |
MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
CL2016002148A1 (es) | Derivados de fenilen-1,5-diamina 2,4-disustituidos y aplicaciones de los mismos, y composiciones farmacéuticas y composiciones farmacéuticamente aceptables preparadas a partir de los mismos. | |
TW201613911A (en) | Heterocyclic compounds and uses thereof | |
WO2016105564A8 (en) | Quinazoline derivatives used to treat hiv | |
MX2017001379A (es) | Producto antiseptico, proceso para prepararlo y su uso. | |
MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
MY189913A (en) | Preparation containing tetracyclic compound at high dose | |
MX2017014035A (es) | Formas solidas novedosas. | |
PH12016501807A1 (en) | Novel compounds | |
MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
PH12016502130B1 (en) | Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect | |
EA201591397A1 (ru) | Хиноксалиноны и дигидрохиноксалиноны как антивирусные средства против респираторно-синцитиального вируса | |
MX2017004655A (es) | Compuestos de hidroxil purinas y aplicaciones de estos. | |
MX2017016619A (es) | Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos. | |
MX2017007377A (es) | Compuestos organicos. | |
TN2016000490A1 (en) | Naphthyridinedione derivatives. | |
PH12016501814A1 (en) | Inhibitors of the wnt signalling pathways | |
MX2017008074A (es) | DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß). | |
PH12016502272A1 (en) | Ceritinib formulation | |
MX2016011572A (es) | Composiciones antimicrobianas de acido organico. |